SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Robson Keith)
 

Search: WFRF:(Robson Keith) > (2010-2014) > Hyperfractionated V...

  • Lannering, Birgitta,1948Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics (author)

Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial.

  • Article/chapterEnglish2012

Publisher, publication year, extent ...

  • 2012

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/164505
  • https://gup.ub.gu.se/publication/164505URI
  • https://doi.org/10.1200/JCO.2011.39.8719DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:125279066URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • PURPOSE To compare event-free survival (EFS), overall survival (OS), pattern of relapse, and hearing loss in children with standard-risk medulloblastoma treated by postoperative hyperfractionated or conventionally fractionated radiotherapy followed by maintenance chemotherapy. PATIENTS AND METHODS In all, 340 children age 4 to 21 years from 122 European centers were postoperatively staged and randomly assigned to treatment with hyperfractionated radiotherapy (HFRT) or standard (conventional) fractionated radiotherapy (STRT) followed by a common chemotherapy regimen consisting of eight cycles of cisplatin, lomustine, and vincristine. Results After a median follow-up of 4.8 years (range, 0.1 to 8.3 years), survival rates were not significantly different between the two treatment arms: 5-year EFS was 77% ± 4% in the STRT group and 78% ± 4% in the HFRT group; corresponding 5-year OS was 87% ± 3% and 85% ± 3%, respectively. A postoperative residual tumor of more than 1.5 cm(2) was the strongest negative prognostic factor. EFS of children with all reference assessments and no large residual tumor was 82% ± 2% at 5 years. Patients with a delay of more than 7 weeks to the start of RT had a worse prognosis. Severe hearing loss was not significantly different for the two treatment arms at follow-up. CONCLUSION In this large randomized European study, which enrolled patients with standard-risk medulloblastoma from more than 100 centers, excellent survival rates were achieved in patients without a large postoperative residual tumor and without RT treatment delays. EFS and OS for HFRT was not superior to STRT, which therefore remains standard of care in this disease.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Rutkowski, Stefan (author)
  • Doz, Francois (author)
  • Pizer, Barry (author)
  • Gustafsson, Göran (author)
  • Navajas, Aurora (author)
  • Massimino, Maura (author)
  • Reddingius, Roel (author)
  • Benesch, Martin (author)
  • Carrie, Christian (author)
  • Taylor, Roger (author)
  • Gandola, Lorenza (author)
  • Björk-Eriksson, Thomas,1960Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xbjoth (author)
  • Giralt, Jordi (author)
  • Oldenburger, Foppe (author)
  • Pietsch, Torsten (author)
  • Figarella-Branger, Dominique (author)
  • Robson, Keith (author)
  • Forni, Marco (author)
  • Clifford, Steven C (author)
  • Warmuth-Metz, Monica (author)
  • von Hoff, Katja (author)
  • Faldum, Andreas (author)
  • Mosseri, Véronique (author)
  • Kortmann, Rolf (author)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för pediatrik (creator_code:org_t)

Related titles

  • In:Journal of clinical oncology : official journal of the American Society of Clinical Oncology30:26, s. 3187-931527-7755

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view